TM 29

Drug Profile

TM 29

Alternative Names: TCAR monoclonal TM 29

Latest Information Update: 10 Aug 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVANT Immunotherapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer; Crohn's disease

Most Recent Events

  • 10 Aug 2000 Discontinued-Preclinical for Autoimmune disorders in Sweden (Unknown route)
  • 10 Aug 2000 Discontinued-Preclinical for Autoimmune disorders in USA (Unknown route)
  • 10 Aug 2000 Discontinued-Preclinical for Cancer in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top